Bayer expands diabetes portfolio in China

Published: 9-Jul-2009
Regulatory Research & Development

Bayer Schering Pharma, Germany has signed an exclusive supply and distribution agreement with Polish insulin producer Bioton and its Singapore-based subsidiary, SciGen, to strengthen its pharmaceutical product portfolio.


Bayer Schering Pharma, Germany has signed an exclusive supply and distribution agreement with Polish insulin producer Bioton and its Singapore-based subsidiary, SciGen, to strengthen its pharmaceutical product portfolio.

For an up-front payment of Euro 31m, Bayer has acquired the exclusive right to market and distribute insulin produced by Bioton under the trade name of SciLin in China. The contract and payment guarantee the exclusive commercial delivery of this recombinant insulin to Bayer in China with a secured supply for the next 15 years.

Andreas Fibig, ceo of Bayer Schering Pharma, said the company already supplies Glucobay for treatment of type 2 diabetes in China and with SciLin will expand its market share in this promising growth market.

There are approximately 40 million diabetics in China. Insulin is the fastest growing segment of the diabetes market in the region, with projected annual growth of more than 40%.

  • Companies:
  • Bayer
See more

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Read more
Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  4. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  5. Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Design & Build

Bayer chooses Fluor and GE Healthcare for new cell culture technology centre

Company will invest US$150 million in new California facility expected to be ready for clinical production in late 2021
Ingredients

Therapeutics: anticancer agent: larotrectinib

TRK (tropomyosin receptor kinase) fusion cancers occur when an NTRK gene fuses with another, unrelated gene, leading to the formation of an altered TRK protein
Ingredients

Therapeutics: darolutamide for prostate cancer

Prostate cancer is the second most commonly diagnosed cancer in men and leads to the fifth highest number of male cancer deaths
Media

Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead

Germany-based pharma major Bayer has recently received the European Commission approval for its haemophilia A long-acting injectable medicine Jivi
Media

TissUse establishes a multi-organ model for risk assessment with Bayer

The biotechnology company has signed a collaboration agreement with the pharmaceutical and life sciences company to develop a liver-endocrine tissue assay
Subscribe now